Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel + Ibrutinib in r/r DLBCL
NCT03876028Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jun 2019
- Primary completion
- Nov 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of tisagenlecleucel in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events and serious adverse events at 24 months and Ibrutinib dose modification following tisagenlecleucel infusion at 24 months. Started Jun 2019; status: terminated.
02
Drugs
tisagenlecleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03876028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03876028.